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Abstract Rheumatoid arthritis (RA) is a painful, chronic
disorder and there is currently an unmet need for effective
therapies that will benefit a wide range of patients. The
research and development process for therapies and treat-
ments currently involves in vivo studies, which have the
potential to cause discomfort, pain or distress. This Working
Group report focuses on identifying causes of sufferingwithin
commonly used mouse and rat ‘models’ of RA, describing
practical refinements to help reduce suffering and improve
welfare without compromising the scientific objectives. The
report also discusses other, relevant topics including identi-
fying and minimising sources of variation within in vivo RA
studies, the potential to provide pain relief including analge-
sia, welfare assessment, humane endpoints, reporting
standards and the potential to replace animals in RA research.
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Introduction
Rheumatoid arthritis (RA) is a painful, chronic autoim-
mune disorder. Current treatments include non-steroidal
anti-inflammatory drugs (NSAIDs), disease-modifying
anti-rheumatic drugs (DMARDs) and biologics, but none
are curative and there is a significant ‘non-responder’ rate
(Strand et al. 2007; Julia` et al. 2009). There is thus a need
to develop more effective treatments for RA. In vivo
studies, using animal ‘models’ of RA, are currently part of
the research and development process for new or improved
therapies and treatments.
However, procedures used to induce arthritis in animals
can cause suffering, which may be mild, moderate or
severe, depending upon the model and the duration of the
study. Implementation of the three Rs (replacement,
reduction and refinement) is thus a priority.
This document complements the literature on good
practice within RA research by providing practical infor-
mation on refinement that is often not included in
publications. It is intended for a wide audience; research-
ers, animal technologists, ethics or animal care and use
committees, veterinarians, funding bodies, regulators and
anyone designing or reviewing studies involving in vivo
models of arthritis worldwide.
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Selecting the most appropriate approach
and ‘model’
As a starting point, it is clearly essential to fully consider
the mechanistic applicability and translatability of the
various in silico, in vitro, in vivo and clinical methodolo-
gies used to address scientific questions relating to RA.
Replacing or avoiding animal use should be a principal
goal, as required in many legislations including European
Directive 2010/63/EU (European Commission 2010).
For example, developments in three-dimensional tissue
modelling show promise for in vitro drug evaluation,
including in anti-inflammation research (Peck and Wang
2013), and in vitro cultures of bovine and human chon-
drocytes and cartilage discs are already used to investigate
mechanisms of cartilage destruction in RA (Neidhart et al.
2000; Pretzel et al. 2009). Synoviocyte models using cells
obtained from human RA or osteoarthritis patients during
surgery have also been developed as test systems for can-
didate therapeutics (Smolian et al. 2001; Ribel-Madsen
et al. 2012). It is important that use of human material is
maximised—especially as fewer replacement surgeries are
conducted in RA because patients are treated more suc-
cessfully with DMARDs and biologics. Biologics with
specific and well-defined molecular targets have also led to
opportunities to replace animal RA models; e.g., analysis
of immune and inflammatory parameters in peripheral
blood mononuclear cells from patients before and after
biologic therapy can reduce the need for animal use in
some cases.
It is good practice to keep up with progress in such
techniques, which can help to replace or avoid animal use,
for example by screening out compounds without thera-
peutic benefit. Databases of in vitro, epidemiological and in
silico models can help with this, e.g., http://www.go3r.org.
If there is no scientifically viable alternative approach,
the choice of animal model should be guided by animal
welfare considerations, aiming to minimise suffering in
addition to the scientific purpose.1 There are useful reviews
of animal models of RA in the literature (Bevaart et al.
2010; Patel et al. 2010; Bolon et al. 2011; Kollias et al.
2011; Vincent et al. 2012). Readers are also referred to
initiatives such as ‘Be The Cure’ (BTCURE), a pan-
European research program to develop new RA therapies
(www.btcure.eu). One of its aims is to develop an infras-
tructure to standardise procedures for generating and
interpreting commonly used RA animal models.
These can be broadly divided into those that are
(i) spontaneous, including mutant and genetically altered
strains, and (ii) induced. Spontaneous models progress
naturally and generally involve a non-resolving, chronic
condition. Induced models may be polyarthritic (involving
a systemic response), which are more likely to be severe, or
monoarthritic (induced by local challenge into a joint).
Species used in RA studies worldwide include non-hu-
man primates (marmosets and macaques), mice, rats,
rabbits, zebrafish, pigs and dogs, but this report addresses
mice and rats as they are most commonly used.
Scientific issues
There is some debate about the optimum in vivo RA models
for particular disease aspects, as well as their translatability
to human disease, with different models possessing different
mechanistic and clinical features (Vincent et al. 2012). If
animal models fail, it may be with respect to clinical pre-
dictivity, or to misapplication of the type of validity
required, be this ‘face validity’ (similarity to the human
disease features of interest), ‘construct validity’ (similar
underlying biological mechanisms) or ‘predictive validity’
(whether there is a similar response to clinically effective
therapeutic agents) (McGonigle and Ruggeri 2014). For
further explanation and discussion of causes of reduced
external validity, see van der Worp et al. (2010). A ‘patho-
genesis map’ for RA to assist with the decision-making
process regarding validity is set out in Vincent et al. (2012).
Ethical and animal welfare issues
A ‘harm-benefit assessment’, in which the potential harms
to animals (i.e., pain, suffering or distress) are considered
against the possible benefits of each project, is commonly
used by regulators and ethics committees to make decisions
about the justification for animal use (e.g., European
Commission 2010; National Research Council 2011). The
project should also have realistic objectives that are
deliverable in practice.
With respect to identifying harms, factors to consider
include:
• whether arthritis is spontaneous or an inducer is
necessary;
• any need to boost or synchronise;
• number and frequency of interventions including
anaesthesia;
• latency to onset of severe outcomes and their subse-
quent duration;
• number of joints affected;
• maximum level of suffering experienced by the animal;
• lifetime suffering experienced by the animal;
• potential to provide analgesia;
• numbers of animals required.
1 Note that in vitro work can also raise ethical and welfare issues,
e.g.,, if primary cell lines are generated or animal serum used for cell
culture.
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The Group considered the welfare impact of poly- and
monoarthritic models, with respect to severity and the
number of joints affected. The consensus was that some of
the classical polyarthritic models (e.g., adjuvant- or colla-
gen-induced models) generally result in a more severe
arthritis and so should only be used as translational tools if
there is strong supporting evidence of a relevant disease
mechanism. Low severity (as opposed to hyperalgesia)
monoarthritic models, including zymosan-induced and
antigen-induced arthritis (Patel et al. 2010; Vincent et al.
2012), possess many relevant disease processes and, being
less severe, should be used instead of polyarthritic models
wherever possible. In addition, if only one limb is affected
then the animal is able to compensate by redistributing
weight between the other three limbs.
Harm-benefit assessments may be more complex for
novel models that are less well established. Some may be
more severe, e.g., the SKG mouse which develops severe
arthritis plus extra-articular inflammation (Yoshitomi et al.
2005), while others can be manipulated to have reduced
severity with greater clinical relevance (e.g., the KBxN
serum transfer model; Montero-Melendez et al. 2011).
Sources of variation in disease development
and progression
A number of factors can lead to variations in the incidence,
severity and timing of arthritis, which can affect the
number of animals needed to obtain a statistically signifi-
cant result. Potential sources of variation, and actions that
can be taken to minimise these, are set out in Table 1.
Refinement of animal models
Once the most appropriate model has been chosen, the next
step is to ensure that refinement is fully implemented. An
effective approach is to set out the whole life experience of
the animal and consider how each potentially painful or
distressing event could be refined, collectively leading to a
significant overall reduction in suffering (European Com-
mission 2012).
Table 2 sets out possible adverse effects within RA
studies, with potential ways of ameliorating these. Sup-
plementary text to explain some of the entries is set out
below.
Housing and care refinements
Husbandry refinements, including appropriate environ-
mental enrichment, benefit animal welfare and should be
provided unless there is sound scientific justification to
withhold them. However, it is essential to evaluate any
effects on data variability (Mikkelsen et al. 2010) and to
allow for these within the experimental design.
Based on the human experience of arthritis, affected
animals should benefit from being able to keep warm and
comfortable, exercise as appropriate and reach food and
water easily. Temperature may be especially important for
animals in RA studies, since healthy mice, given an
opportunity to select their thermal environment, choose an
ambient temperature of 30–31 C, considerably above the
range in most facilities (Gaskill et al. 2009, 2012). This
suggests that it is good practice to review ambient tem-
perature levels for rodents in RA studies and provide a
sufficient quality and quantity of nesting material. Besides
the animal welfare implications, the systemic sympathetic
response to cold stress can affect data quality in studies
relating to immune function (Karp 2012; Kokolus et al.
2013), and it is worth considering how this might also
apply to RA projects.
Regarding enrichment, shifting attention away from
pain benefits human patients (Ulrich 1984; Chan et al.
2012; Havey et al. 2014), and distraction from pain also
modulates pain perception in animals (Gentle and Tilston
1999; Ford et al. 2008). An appropriately stimulating
environment will therefore likely help to improve welfare
and reduce pain perception in animals on RA studies.
Standard principles for housing, husbandry and care of
mice and rats used in RA studies are:
• Soft litter, to reduce pain on walking.
• Sufficient soft, non-tangling nesting material to keep
comfortable, cushion sore joints and enable
thermoregulation.
• An appropriate group of cagemates for social animals,
depending on age, sex and strain.
• One or more refuges, to permit natural behaviour and
alleviate potential anxiety in animals with compro-
mised mobility.
• Effortless access to easy-to-eat food and water, to cater
for disability.
• Appetising food, to counteract or prevent weight loss.
• Proactive welfare management as opposed to reactive.
For example, animals should be acclimatised to cage
provisions, appetising food and hydration agents before
arthritis is induced.
Defined sources of enrichment items should be used,
because contaminants (e.g., dioxin), present in some oils
and bleaching agents, can act as confounds (e.g., by
affecting Cyp1A1 gene activity; Tischkau and Mukai
2009). Standardisation can be managed in the same way as
regulatory toxicology studies, in which in-house Quality
Assurance groups set limits of acceptability for different
substances in litter, nesting materials and enrichment items.
These limits are used to review Certificates of Analysis that
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Table 1 Sources of variation in animal models of RA
Sources of variation Ways of addressing these
Protocol
Variation in protocols for inducing arthritis Search the literature for suitable standardised protocolsa and
consult colleagues
Monitor progress with initiatives such as BTCURE
Different protocols for assessing outcomes, e.g., with respect
to clinical assessment, welfare assessment or histopathology
Research accepted assessment methods, ensuring
discriminative power (see below)
Adapt the histopathology score to the specific model
Different protocols for assessing therapy efficacy, given that
the relevance of the drug target depends on the underlying
mechanism
Research the appropriate efficacy measure for each target and
define outcome-based assessment criteria for potential
therapies, e.g., clinical scores or cellular responses
Environmental disturbance due to husbandry, scientific
procedures and observations, or maintenance/construction
work
Keep noise to a minimum
Capture and handle animals with care
Minimise the number of technical acts (e.g., administration of
substances and anaesthesia)—but not by increasing the
impact on the animal (e.g., without excessive dose volumes)
Reduce husbandry and maintenance procedures, like cage
cleaning and cleaning animal rooms, to the minimum
necessary for good health
Find out when cages and rooms are cleaned and avoid
conducting procedures immediately afterwards
Statistical power Conduct power calculations, use appropriate numbers, and
define appropriate statistical analysis at the project planning
stage. Plan for ‘dropouts’
Use pilot experiments, where appropriate, to define acceptable
limits of severity and ensure statistical power
Variation in batches and quality control of biologicals such as
collagen, lipopolysaccharide and Mycobacterium
Only use defined and/or batch tested biologicals, ensuring they
are in date
Animals
Different species, strains, sexes or ages of animals
NB Some outbred strains are cheaper than inbred and can
respond with arthritis—but due to genetic variability,
severity can range from no response to extreme
Search the literature to help select the appropriate animal—but
be critical and do not simply follow tradition; research and
review current approaches with respect to species, sex, strain
and age
Use inbred strains to reduce variability and extremes in
responses
Lack of proper colony management, leading to (i) genetic
contamination (ii) incomplete inbreeding or (iii) genetic
drift, resulting in unpredictable variations in susceptibility
Ensure good colony management; ‘refresh’ in-house colonies
periodically by returning to founder stock; ensure frequent
genotyping of generations
Consider establishing a colony for long term projects, but
ensure overbreeding and wastage are minimised
Variations in health status, e.g., pinworm infection Apply good health care and colony management, led by animal
technologists and the attending veterinarian
Environment
The length of time that animals have spent in the facility; i.e.,
animals housed for longer before induction may be more
susceptible to arthritis in the case of collagen models
See comments for ‘variation in protocols for inducing arthritis’
above
Level of biocontainment, i.e., whether in individually
ventilated cages (IVCs) or conventional microbial
environment
Be aware of model-specific pros and cons, e.g., mouse C57Bl6
CAIA seems to require IVC housing, but the SCW model
may be more responsive in an open-top cage environment
Type of litter, nesting material, enrichment items and diet;
interactions with humans
Ensure that these are carefully selected and adequately
described in publications (see Sect. 3)
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accompany such materials. Describing the sources of all
materials that are provided will help others to interpret the
results and conclusions of publications (Hutchinson et al.
2005).
Catching animals prior to handling
It has been demonstrated that being caught by the tail is
stressful for mice and induces anxiety (Hurst and West
2010; Gouveia and Hurst 2013). Avoiding capture by the
tail in RA studies, by catching and restraining using cup-
ped hands, tunnels or Vetbed, could thus decrease stress
as well as reducing the risk of causing discomfort through
involuntary extension/flexion of arthritic joints, or if ani-
mals have been injected close to the tail base.
Arthritis inducers and their administration
Local adverse effects due to inducers can be minimised by
reducing the dose, volume and frequency of administration.
The feasibility of this approach depends on the nature of
the antigen, its solvent, and the adjuvant, and can be
evaluated in pilot titration studies, using scoring systems to
monitor the onset and severity of arthritis.
Regarding administration, wide gauge needles cause
more pain and increase the risk of ‘tracking’, where a
tunnel remains under the skin following withdrawal. The
inducer can leak into this, causing irritation and further
discomfort or pain. To avoid tracking, withdraw the needle
slowly and smoothly, applying slight pressure with the
thumb. Mycobacteria for adjuvant and collagen-induced
arthritis should be ground very finely to prevent ‘stacking’
in finer needles (Brand et al. 2007) and consequent vari-
ability in incidence and response. NB Care must be taken
when alternating between strains of Mycobacterium, as M .
butericum can induce more severe rat adjuvant disease than
M. tuberculosis.
Many protocols use intradermal injection, but this leads
to a higher incidence of ulcers, especially if administered
close to the tail. In the experience of Group members,
subcutaneous injection at single or multiple sites further
from the tail (e.g., on the flank) can reduce ulcer incidence
while still reliably inducing arthritis. This may be possible
in some studies that do not depend on intradermal injec-
tion, and a pilot study to evaluate an alternative
administration protocol may be justifiable. If there is sci-
entific justification for intradermal injection, sites should be
chosen with care, taking into account both the animal’s
movements and areas that will be affected during restraint.
Study duration
Refinement can also be achieved by reducing the duration
of experiments, provided this is compatible with the study
aims, i.e., all the necessary data can be obtained within the
study time. There may also be scientific reasons not to
Table 1 continued
Sources of variation Ways of addressing these
Operator effects
Variations in performance of techniques, with respect to
expertise or level of awareness of correct protocol—an
establishment ‘culture’ issue
Ensure that good practice is observed with training,
supervision, assessment of competence and Continuing
Professional Development, seeking advice both internally
and externally as necessary
Account for any variation in experimental design; block by
operators (personnel conducting each procedure)
Other sources of variation
Unexplained variation between different facilities using the
same protocols, sexes and strains
Ensure good attention to detail at all steps when inducing
arthritis
Liaise with external colleagues and compare how protocols are
interpreted
Discuss the animals’ experiences with animal technologists
and care staff to identify differences in husbandry protocols
Monitor and compare physical environments, e.g., noise,
temperature fluctuations
Conduct a full health screen of animals
Ensure that publications include an appropriate level of detail
to help interpret results if differences persist
a Standardised protocols can help to promote consistency, but should be critically considered every time. ‘Standardised’ does not always mean
‘fit for purpose’, and standard protocols may involve greater animal numbers or suffering than is desirable. An alternative approach to
standardisation between facilities is for each to use models that enable good reproducibility with minimal suffering, and regular refinement,
ensuring that protocols are written up in adequate detail. This approach also further disseminates information about good practice
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Table 2 Adverse effects and refinement
Potential adverse effect How this may be refined
Administration of RA inducer
Capture, handling and restraint Competent, empathetic capture and handling (e.g.,
capture by cupping or tunnel, not tail)
Habituation to handling and restraint
Pain due to administration of inducer (intradermal
or subcutaneous injection)
Use gaseous anaesthesia for intradermal routes, to
reduce pain and increase accuracy
Inject intradermally into the rump, not the tail base. If
the site is painful, capture or restraint by the tail will
hurt
Keep volumes and doses to the minimum necessary; it
is better to use multiple sites if larger volumes are
needed—but not too close together as injectates can
coalesce, causing granulomas
Ensure injectate has been formulated so as to minimise
swelling and pain
After effects of anaesthesia e.g., dehydration,
inappetence
Give treats such as Nutella or sunflower seeds
Ensure animals can reach water or food with high water
content such as wet mash, transgel, satsuma segments
Provide oral glucose or rehydration with saline if
necessary
Monitor body mass and dehydration
Pain or ulceration around injection site Inject into the rump for less risk of ulceration;
additional injections can be into the flank if needed
Never inject into the foot—this is too painful and not
necessary
If animal pays attention to injection site, apply topical
local anaesthetic and review anaesthesia and injection
protocol
Ulceration should heal after 4 to 7 days—if not,
implement a humane endpoint based on
characteristics and persistence (see Sect. 7)
Consider needle gauge with care and avoid ‘tracking’;
implement humane endpoint if significant tracking
Administration of inducer by intraperitoneal
injection
This is ‘going blind’ and adequate training is essential
in order to avoid injecting into an organ or the gut.
Never administer Freund’s complete adjuvant (FCA)
via this route
Specific adverse effects due to adjuvant, e.g.,
granuloma, irritation, lesions
Use the least harmful adjuvant possible—monitor the
literature for alternatives and challenge the use of
problematic compounds like FCA
Shaving while under anaesthesia, immediately before
injection, helps to monitor adverse effects if these are
likely
Trial using incomplete Freund’s adjuvant for a less
severe reaction
Effects of lipopolysaccharide ‘boost’—may be
‘shock’-like cytokine storm
Provide additional nutritional and hydration support for
animals before injection
Define appropriate humane endpoints
Monitor body mass and dehydration, remove faecal
plugs
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prolong studies, due to the risk that the disease will enter
the ‘repair phase’, with associated periostitis or ankylosis
that can confound the results.
Adverse effects of RA models
Some factors that require special attention are set out
below.
Boosting
Boosting is not used in rats, but is sometimes used in mice
to support antibody-induced collagen induced arthritis, or
to synchronise the collagen-induced arthritis (CIA) model.
Boosting commonly takes the form of an intraperitoneal
injection of lipopolysaccharide (LPS) or subcutaneous
administration of collagen in Freund’s incomplete adjuvant
(FIA); Freund’s complete adjuvant (FCA) should not be
used due to the challenge response to the adjuvant.
Administering LPS is stressful and induces cytokine
release that can cause severe adverse effects including
shock, diarrhoea, and malaise. Animals may not drink, and
may develop faecal plugs that, coupled with diarrhoea, can
be life-threatening if not checked regularly and cleaned
away. However, there may be justification for using LPS if
it allows study duration to be reduced and/or fewer animals
used because the incidence of arthritis is reliably increased.
Collagen/FIA boosting should be subcutaneous, and can be
refined by restricting sensitisation to one side of the animal
and administering the boost at a separate site. The choice of
ligand should also take translatability and adverse effects
into account; for example, the various TLR ligands may
model different aspects of RA more effectively than more
Table 2 continued
Potential adverse effect How this may be refined
Effects of arthritis
Painful joints, sore feet, lameness, disability and
distress
For intra-articular induction protocols only induce in a
single joint
Implement husbandry refinements, e.g., weighing boats
to sit in, refuges designed so that animals do not have
to turn around, long nozzles on drinking bottles, soft
sawdust litter, short and soft nesting material (long
strands can wrap around sore legs)
Provide soft, appetising diet or diet gel (accustom
animals to this before the acute phase)
Pick up and handle using washed Vetbed
Handle very gently and empathetically
Give analgesia if possible (see Sect. 5)
Refine humane endpoints; include consideration of
study duration and the level of disease severity
necessary to answer the scientific question
Acute pain Provide analgesia if possible, e.g., opioid during ‘attack’
phase
Provide appropriate environmental enrichment, and
group housing for social animals, to help shift
attention from acute pain
Other welfare issues
Behavioural problems, e.g., aggression Question scientific justification and necessity for using
aggressive strains, or male mice of some strains e.g.,
DBA1, C57BL/6
Use littermates where possible
Review husbandry with respect to group size and
number/design of refuges
If single housing is necessary for welfare reasons,
ensure animals have adequate enrichment, especially
a refuge and plenty of nesting material
Remove aggressors if necessary
Inherently severe arthritis in particular models,
e.g., spontaneous SKG mouse, and species or
strains (e.g., Lewis or DA/Ola rat)
Explore potential to answer the same question using a
less severe model, e.g., Methylated Bovine Serum
Albumin (mBSA) model, or a less susceptible strain
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commonly used agents such as LPS or FIA, but may have
different adverse effects.
Acute phase of arthritis
Animals experience the most severe pain during the acute or
‘attack’ phase, during which they need close monitoring
and additional care, including analgesia if feasible (see
Sect. 5). Most therapeutic studies are carried out during this
acute phase and it is not usually necessary to extend them
into the chronic, resolving phase (see below). The severity
of the acute phase should be refined to provide the required
statistical power for the primary outcome and not more.
Resolving phase
If polyarthritis models are taken into the ‘chronic resolv-
ing’ or ‘recovery’ phase (e.g., to study bone remodelling),
the impact on the animal must be carefully considered. The
consequences of periostitis become more prominent
(especially in rat adjuvant arthritis) as aberrant bone out-
growths develop within the paws and along the bone shafts.
Although acute inflammation may have receded, periostitis
and spondyloarthropathies are painful and add significantly
to the lifetime severity.
Joint damage can be so severe in polyarthritis models
that resolution to normality is impossible. Low acute-load
models should be used to investigate factors influencing
resolution, as they allow mechanisms in joint resolution to
be seen as well as causing less suffering (Montero-Me-
lendez et al. 2011).
Control groups
In studies of potential therapeutics, animals in control
groups that do not receive the candidate therapeutic agent
will develop the most severe form of disease and are of
special concern. The requirement, and humane endpoints,
for controls should be very carefully considered. In some
fields, controls can be avoided by using ‘historic’ controls
from the literature or the same institution. Unfortunately, in
RA studies this is likely to mislead due to variations
between institutions, contemporaneous environmental fac-
tors, and the protocols used. However, sharing control
groups from different, contemporary experiments within
the same institution is valid, and should be encouraged,
provided they possess sufficient power.
Aggression
Inappropriate enrichment can cause aggression in male
mice (Marashi et al. 2003), and male DBA/1 and
C57BL/6 mice, both of which are used for experi-
mental arthritis, are especially prone to aggression.
However, the risk can be reduced by establishing
groups early, using littermates, ensuring that animals
are not subsequently mixed and selecting appropriately
designed refuges. For mice, two refuges or dual entry/
exit designs can defuse aggression (T Boden pers.
comm.), but if it persists, it may be necessary to
remove aggressor(s) since fighting may cause stress,
injury and infection—which can all influence arthritis
development. Aggression between arthritic rats is not
expected and indicates a serious welfare issue that
should lead to a review of husbandry and experimental
protocols.
Adjuvant arthritis
Adjuvant arthritis models, such as intradermal/subcuta-
neous administration of CFA to rats, or pristane to rats and
mice, can easily lead to severe outcomes. Severity may be
reduced by refining the initiation doses, e.g., reducing the
dose of pristane for pristane arthritis, without compromis-
ing the arthritis outcomes (Malik et al. 2011).
The severity of CFA arthritis in rats can be compounded
by systemic disease that, if uncontrolled, includes liver
granuloma (which can affect Cyp enzyme activity), skin
disease, splenomegaly, ulceration at the injection site, tail
lesions, eye disease and disuse of the hind paws leading to
dragging (‘sledging’), and ulceration of the hind feet.
Although there are welfare concerns, there may be
scientific benefits to consider as part of a harm-benefit
assessment. The ‘structural validity’ of CFA-induced
arthritis is different to other models (Patel et al. 2010)
with cell mediated immune responses predominating,
which may benefit the scientific objectives of some
studies. In addition, drug responses can be more easily
distinguished (Bolon et al. 2011), and when inbred strains
are used responses tend to have low variability, with
robust incidence and very predictable disease onset. These
points mean that numbers do not need to take variability
into account, so can be kept lower than for murine
models. Therefore, there may be scientific justification for
using CFA, but this should be very closely scrutinised and
every opportunity taken to reduce suffering; pilot studies
may be advisable before using this model for the first
time.
Older publications describe the injection of the inducer
into one hind paw, inducing the ‘primary response’, a
chronic granulomatous reaction. The ‘secondary response’
of inflammation in the contra-lateral paw reflects the sys-
temic arthritis. This protocol is incapacitating, can lead to
severe disease, and should not be used.
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Arthritis in genetically altered (GA) strains
Some GA strains require careful monitoring, as the severity
of arthritis may be unexpectedly severe or chronic. For
example, prostaglandin-D2 synthase knockout mice have
an exaggerated delayed-type hypersensitivity response,
which would be predicted to result in severe disease if
expressed in collagen arthritis (Trivedi et al. 2006); indeed,
PGD2 antagonism exacerbates disease (Maicas et al. 2012).
Where exacerbation of disease is expected in a GA line,
models or protocols of reduced severity, such as monoar-
ticular or reduced inducer dose, should be used wherever
possible.
Analgesia in models of RA
All arthritis models involve pain and some are in fact used
as models of inflammatory pain (Colpaert 1987; Honore´
et al. 1999). Some pain can be attributed to the acute
inflammatory response, but chronic pain may also develop,
with hyperalgesia associated with a variety of neuro-
chemical changes in the spinal cord (Colpaert 1987;
Honore´ et al. 1999; Christianson et al. 2010; Bas et al.
2012). This is evidenced by the fact that rats and mice
continue to self administer analgesics in the resolving
phase, even though paw swelling has abated (Colpaert et al.
2001; Wooley et al. 1981). The goal of analgesia in RA
studies is to minimise acute and chronic pain without
having a significant negative impact on scientific validity.
Analgesics and scientific validity
Most analgesics affect the immune system in some fashion
(Paska et al. 1986; Earl et al. 1994; Dinda et al. 2005;
Pulichino et al. 2006), so there can be concern about pro-
viding analgesia for fear of introducing a confound.
However, there is increasing evidence of effects upon
many body systems (including immunity) of unrelieved
pain and distress in animals, and how these can influence
the experimental outcome (Baumans et al. 1994; Liv-
ingston and Chambers 2000; NHMRC 2008; Ren and
Dubner 2010). It is also noteworthy that analgesics are
rarely excluded from human clinical trials, which are
therefore subject to the same confounding influences.
The authors therefore propose that analgesia should be
used unless there is sound scientific justification otherwise,
e.g., if it can be demonstrated that analgesia would make it
difficult to attribute therapeutic effects to the study com-
pound, or if a class of analgesic could affect unpredictably
the disease severity in studies using GA animals. For a
discussion of decision making regarding pain alleviation,
see Carbone (2011).
Pain relief protocols can be designed to minimise
potential impact on the scientific objectives. For example,
analgesia can be tailored to periods when inflammation is
at its peak and likely to be especially painful (Khachigian
2006; McCarthy et al. 2012), with administration in
anticipation of (rather than in response to) the pain in order
to increase efficacy.
Potential analgesics for RA studies
When considering whether to provide analgesia, two
essential questions are (i) what effects occur at analgesic
doses, and (ii) will these necessarily invalidate experi-
mental outcomes? There are a number of reports of the use
of analgesics in arthritis models without negative impacts
on the experiment; some examples are set out below.
Gabapentin has been found to be effective in the
attenuation of allodynia during the chronic phase of murine
K/BxN arthritis (Christianson et al. 2010) and has also been
shown not to interfere with the immune response (Van Loo
et al. 2006). Gabapentin, the NSAID ketorolac and the TNF
receptor antagonist Etanercept (R) have all been reported
as effective during the acute phase, whereas gabapentin
alone was effective on allodynia in the chronic phase
(Christianson et al. 2010). Since NSAIDs are anti-inflam-
matory and can have DMARD activity (Seed and Burnet
pers. comm.), anti-TNF is antirheumatic, and both are only
effective in the acute phase, gabapentin could be used.
Buprenorphine, a partial agonist opiate, does not pre-
vent the development of a reliable arthritic response in
mice when administered in drinking water (M. Burnet,
Synovo, pers. comm., see below), but neither direct com-
parisons with non-treated mice, nor effects on joint
histopathology, have been assessed. Buprenorphine
reduced spinal neuronal discharges and reduced allodynia
during the acute and chronic phases of mouse CAIA (Bas
et al. 2012). However, oral administration of buprenor-
phine at analgesic doses (2 mg/kg twice daily) in rat SCW
arthritis inhibited inflammation and joint erosion (Volker
et al. 2000).
Paracetamol (acetaminophen) is potentially a suitable
analgesic, since it possesses less anti-inflammatory activity
than NSAIDs and COX-2 inhibitors. Paracetamol at
50 mg/kg significantly reduced nociceptive evoked and
spontaneous spinal discharges in adjuvant arthritis
(McQueen et al. 1991). It also reduced inflammatory
hyperalgesia without affecting carrageenan inflammation
and central hyperalgesia (Bianchi and Panerai 1996).
Therefore, it is possible to provide analgesia in some RA
studies, and some institutions apply analgesia routinely.
However, further research is needed into suitable analgesic
regimes, including evaluations from the time of induction,
or specifically the attack and chronic phases, to assess
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analgesic efficacy and dissociate these from arthritic out-
comes. If in doubt, the veterinarian should be consulted,
literature searched and pilot studies conducted if necessary.
Pilot studies
Pilot studies could establish whether analgesia might be
provided at one or more stages of an RA study without
significantly compromising the science. Although the ani-
mals in the full study will benefit if it is shown that pain
relief is feasible, pilot studies to evaluate this will cause
suffering and should undergo a harm-benefit assessment,
with full implementation of the three Rs. Ideally, the pilot
study should be designed such that data from it could
potentially be incorporated into the main study, to avoid
using ‘extra’ animals.
Administration of analgesics
There are three main options for analgesic administration;
parenterally or orally by either gavage or self-administra-
tion. There are pros and cons associated with each of these
routes (Table 3). For guidance on administering analgesia
in nut paste (e.g., Nutella), see Jacobsen et al. (2011) and
Abelson et al. (2012). Others have reported providing
buprenorphine in the usual diet (Molina-Cimadevila et al.
2014).
Assessing animal wellbeing, pain, suffering
or distress in RA studies
Species and strains vary regarding susceptibility to arthritis
and how pain-coping behaviour is expressed. An effective
day-to-day welfare assessment system should therefore be
tailored to the species, strain and protocol, with input from
the researcher(s), animal technologists and the veterinarian
(Hawkins et al. 2011; European Commission 2012, 2013).
All those responsible for assessing animals should receive
adequate training in recognising indicators of suffering
associated with each project and in using the relevant
recording systems.
Assessment often involves handling, and animals used
in RA studies may be in pain, so they should be habituated
to empathetic, careful capture and manipulation. For
example, mice or rats with swollen paws should never be
picked up from cage lids. However carefully it is done,
handling animals during the attack phase is still likely to be
Table 3 Advantages and disadvantages of parenteral versus self-administration of analgesics in RA studies
Method Advantages Disadvantages
Parenteral
administration
Can be reasonably certain that required
dose has been reliably delivered
New slow-release opioid preparations are
being developed which may offer
prolonged and sustained analgesia
without the need for re-dosing
Capture, handling and restraint for administration may
be painful and stressful, especially in the attack phase
or if animals are in chronic pain
Painful injection, risk of infection, risk of reduced
disease on repeated administration
A ‘standard’ dose may not be appropriate for the
individual
Orally by gavage Can be reasonably certain that required
dose has been reliably delivered
Does not require injection
As for parenteral administration, plus gavage procedure
can be distressing
Some physical risk to animal, e.g., misdosing into
trachea, damaging oesophagus
Self-administered in
watera or diet
No handling or restraint required
Involuntary self administration, or can
train animals to recognise water with
analgesic
Animals can dose themselves optimally
Cage intake easily measurable
Individual intake unknown
Severe pain could reduce ability to access food or water
and thus analgesia
May be issues with absorption or bioavailability
Self-administered in
‘treat’ food
No handling or restraint required
Can accustom animals to taking treats
(e.g., jelly, Nutella) so that they will
readily self-administer
Animals can dose themselves optimally
As for self-administration in water/diet
May not readily take treat with analgesic
Rate of intake can vary with several factors, e.g.,
position in group hierarchy
a Example regimes; 240 mg paracetamol in 140 mL drinking water, or 1 mg/L buprenorphine in 150 mL water per diem (T Boden; M Burnet,
Synovo GmbH, pers. comm.)
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painful, so a compromise is needed between ensuring
adequate assessment and minimising (or even avoiding)
catching and handling. Some indicators can be assessed
without handling, such as ‘pain faces’ (below). Note that
mice and rats are nocturnal and most active during the dark
phase, so important behavioural signs may be missed if
animals are only observed when it is light.
The monitoring protocol will also depend upon the study
phase, e.g., one author’s facility assesses animals three
times a day during the acute phase of CAIA following LPS
administration. If ‘rescue analgesia’ has been agreed, daily
full assessment (involving handling) is necessary to
recognise when pain relief is required. Post-acute phase,
animals are generally monitored daily with less frequent
detailed assessment. An example regime is assessment
every other day from days 5 to 25 and twice a week from
then, provided the animal’s condition has stabilised. After
the acute phase, animals should be weighed and body
condition scored on assessment days.
Suitable welfare indicators for mice and rats in RA
studies
The European Commission (EC) Expert Working Group on
Severity Assessment guidance on recording clinical
observations sets out ‘high level’ categories of observa-
tions, which are then broken down into areas to focus on
when observing animals, then specific indicators to monitor
within each area (European Commission 2012). Table 4
lists indicators from the EC guidance identified by Group
members as most relevant to RA studies, categorised
according to the EC system.
The EC has also published a worked example of this
approach for Type II CIA in rats (European Commission
2013), and ‘‘Appendix’’ to this document sets out an
example hypothetical ‘score sheet’ for mice using some of
these indicators. Note that this is a generic example, not
suitable for use without adaptation and tailoring to the
species, strain and protocol. Some of the indicators and
their applications are explained further below.
Weight loss
Animals on RA studies may lose weight, or weight may
remain stable when an animal should be growing, either of
which can be a concern. Scores are generally assigned for
percentage weight loss. It is good practice to obtain the
baseline weight for each animal and note the weight at which
to implement the humane endpoint. In growing animals, it
may be necessary to compare with age-matched controls.
Body condition scoring can be used to assess body fat
and/or muscle mass loss (Ullman-Cullere´ and Foltz 1999),
but this involves handling and palpating animals which
may be painful. Discomfort can be reduced by using a
clean piece of Vetbed to restrain animals, or to rest them
on during handling.
Running wheels
Reduced levels of running wheel use can infer levels of
joint pain (Krug et al. 2009; Whittaker and Howarth 2014),
but there is currently debate about running wheels as ‘en-
richment’. Some view them as providing additional
activity, and in the experience of one author wheels help to
reduce aggression. However, there are concerns that wheel
running is an abnormal, and possibly addictive, behaviour
because animals spend long periods running, sometimes to
the detriment of other behaviours (Sherwin 1998; Wu¨rbel
2008; Richter et al. 2014). The utility of running wheels as
an indicator of RA progression may justify providing them,
provided that average group data are obtained rather than
singly housing social animals to acquire individual data.
‘Pain faces’
Research is ongoing into ‘pain faces’ in a number of spe-
cies. A mouse grimace scale (MGS) and rat grimace scale
(RGS), including elements such as ‘orbital tightening’ and
‘nose bulge’, have been developed for use when animals
are experiencing acute pain (Langford et al. 2010;
Sotocinal et al. 2011; Whittaker and Howarth 2014). These
Grimace Scales can be useful for assessing animals in
chronic pain if this also includes acute episodes. At one
author’s establishment the MGS is displayed in procedure
rooms to help staff assess animals.
Disturbed sleep
Disturbed sleep has been noted in animals on RA studies
(Andersen and Tufik 2000). It is unlikely that many facil-
ities will have the resource to monitor sleep patterns at
present, but non-invasive biotelemetry systems and beha-
vioural monitoring software are both developing rapidly
and may become more accessible. Such systems could also
be used to monitor animals when active at night.
Swollen paws
Animals should be very gently caught and handled, and
paws checked daily, from around day 14 following the
initial induction (or from the point of inflammation). The
digits and joints should be examined, and if there is
swelling it should be noted how high up the limb this is
present. Swelling may be measured with (preferably non-
spring) callipers or by plethysmometry, as swollen paws
are painful (Bolon et al. 2011) (Fig. 1). Swollen paws and
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digits may also be accompanied by reddening of the skin
(Fig. 2).
An example approach to visually monitoring clinical
scores of the hind paws in pristane adjuvant arthritic rats is
outlined below (Table 5; Fig. 3). In this trial, all joints
were assessed in order to determine an optimal scoring
system relevant to that model, as different joints develop
and resolve arthritis at different times.
In mice, distinguishing individual joints is difficult
without handling animals and touching the paws. However,
in the authors’ experience an assessment system for mice in
which whole paws are scored (Fig. 4) was as robust as a
Table 4 Useful indicators for welfare assessment of mice and rats used in RA studies
High level
category
Areas to focus on when observing animals Specific indicators to monitor
Appearance Body condition Weight loss and/or loss of body condition
Coat and skin condition Ulceration
Faecal or urine staining
Unkempt or greasy coat
Scabbing, ulceration, infection at injection site associated with
adjuvant
Skin tenting (dehydration)
In adjuvant arthritis, crusting or lesions around eyes, ears, paws, tail;
tail ‘ribbing’ (changes in connective tissue)
Paw ulceration
Discharge Ocular discharge
Other ‘Pain face’, e.g., semi-closed eyes and nose bulge in mice
Body functions Respiration Dyspnoea or tachypnoea
Food/water intake Reduced
Body temperature Decreased temperature, indicated by observing shivering or use of
thermography
Environment Enclosure environment, including any litter, nesting
material, enrichment items
Soft faeces or diarrhoea; or lack of faeces (constipation)
Poor quality nest
Reduced use of enrichment items such as chew blocks
Behaviours Social interaction Change in temperament or responsiveness.
Pain can have varying effects e.g., reduced aggression to conspecifics,
or increased aggression towards humans
Isolated or withdrawn from conspecifics
Posture and mobility Lethargy
Reduced wheel running
Other Vocalisation; spontaneous or invoked
Sleep disturbance
Less willing to take treats or to incorporate new material into nest
Procedure-
specific
indicators
Indentified on the basis of the individual project, its
potential adverse effects and expected indicators of
these
Abnormal gait (e.g., ‘sledging’ in severe cases)
Abnormal posture
Paw swelling
Clinical indicators e.g., data from von Frey tests, gait analysis
apparatus and software, data from imaging joints
Analgesia self-administration, where applicable
Serum biomarkers, if available as part of the project, could be used to
provide additional information about disease progression—but
blood samples should not be taken solely for this purpose
Free
observations
A severity assessment scheme should always include a facility to note any observations of unexpected
indicators of suffering
Indicators in bold are especially relevant with regard to humane endpoints
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protocol that scored individual digits and joints (see ‘‘Ap-
pendix’’). ‘Global’ scores for each paw, tailored to
individual projects, can therefore be used for mice,
avoiding handling.
Infrared thermography (using a video camera) has been
suggested to monitor clinical severity, as foot temperature
can be correlated with the degree of swelling (Jasemian
et al. 2011). Thermographic images can be taken without
anaesthesia, restraint or otherwise handling the animals,
with welfare advantages if joints are painful.
Self-administration of analgesics as a welfare indicator
Analgesia self-administration can indicate discomfort or
pain (Whittaker and Howarth 2014), either if self-admin-
istration is part of the project, or if pain relief can be
provided during at least part of the study. It may be justi-
fiable to conduct a pilot study using analgesic self-
administration to validate behavioural indicators of pain
(Colpaert et al. 1980, 2001), even if analgesia cannot then
be provided during the actual study.
Humane endpoints
‘Humane endpoint’ can be defined as ‘the point at which an
animal’s pain and/or distress is terminated, minimised or
reduced, by taking actions such as killing the animal
humanely, terminating a painful procedure or giving
treatment to relieve pain and/or distress’ (see http://www.
humane-endpoints.info).
The humane endpoints for each study will depend upon
factors including its aims, the stage at which sufficient data
are obtained, and sometimes whether a predetermined
Paw swelling (mL) 
2.5 – 4  
1 – 1.2 
0.4 – 0.6 
Fig. 1 Degrees of paw swelling in FCA adjuvant arthritic rats,
measured using plethysmography. This illustrates significant, but well
controlled, paw swelling to 2.5 mL. Volumes above this are likely to
cause severe pain and debilitation and should be considered a humane
end point, as in the top paw. (From Bolon et al. (2011), reproduced by
kind permission of Hindawi Publications Corp.)
Fig. 2 Appearance of rat hind paws with arthritis following different
doses of pristane. a Note swelling, redness and start of skin lesions.
b Ankylosis at the chronic phase; histology shows active inflamma-
tion. The animals shown in a and b reached the humane endpoint and
were humanely killed. c Well managed arthritis. The development of
severe arthritis with lesions, as in a, is not required as power can be
maintained with lower doses of pristane as in c, also reducing
variability. (Courtesy M. Seed, University of East London)
Table 5 Example scoring
scheme for investigating the
pattern of paw involvement in
pristane arthritis, using DA rats
to determine outcomes for the
full trial. This can be adapted
for use with other models
Arthritis score Maximum points—hindpaws Maximum points—forepaws
1 point for each swollen or red digit 5 4
1 point for each swollen knuckle 5 4
1 point for swollen midfoot 1 1
1 points for a swollen ankle/wrist 1 1
Total (92) 24 20
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‘severity limit’ has been reached. Local ethics or animal
care and use committees may also have input into defining
humane endpoints. However, the authors believe that there
are some generally applicable limits regarding specific
adverse effects in RA studies, at which point animals
should be humanely killed. These are listed in Table 6.
Other indicators are commonly used in combination to
implement humane endpoints, but some involve subjective
judgements and using several indicators requires careful
consideration. A ‘score sheet’ approach, either noting
whether indicators are present/absent or assigning numer-
ical scores to these, can provide a useful adjunct to
competent and empathetic human observers by helping to
improve objectivity (see Sect. 6).
A number of judgements will need to be made includ-
ing: the numerical score at which an animal should be
humanely killed; whether one or more factors should be
weighted; and whether and how duration should be taken
into account (e.g., how long to maintain a medium/high
scoring, but below threshold, animal). Issues like these
should be discussed by the researcher, veterinarian, animal
technologists and care staff, with appropriate input from
the regulator and ethics or animal care and use committee.
Experimental design and reduction
Good experimental design is critical with respect to ensuring
that projects are statistically robust, and that the correct
number of animals is used to achieve the experimental
objectives—neither too many, which causes avoidable suf-
fering; nor too few, which is unethical if it means that
animals are used in projects that have no significant benefit.
For generic guidelines and principles to apply at the project
planning stage, see Festing et al. (2002), Bate and Clark
(2014) and the ARRIVE guidelines on reporting animal use
(Kilkenny et al. 2010). Although ARRIVE primarily relates
to writing up in vivo research, it is also a useful study design
checklist and is available within the UK National Centre for
the three Rs (NC3Rs) resource hub on experimental design;
see http://www.nc3rs.org.uk/experimental-design.
In practice there are different, and sometimes competing,
factors to take into account when determining appropriate
numbers, including the experience of each individual
Fig. 3 System for recording paw scores. An example of a scoring
system that can be used in pilot rodent trials to determine the pattern
of disease expression and evaluate different scoring systems and
determine power. The top rows represent the digits, second rows are
the knuckles, and third and fourth rows are the midfoot and ankle/
wrist respectively. The scores in this case are: left front 4, right front
0, left hind 4, right hind 3 (courtesy M. Seed, University of East
London)
Fig. 4 Appearance of mouse
front paws with progressively
severe CIA arthritis. In this
example scheme, 0 normal, 1
digits swollen, 2 digits and pad
swollen, 3 wrist/ankle, pad and
digits swollen. (Courtesy Remi
Okoye, Alex Vugler; UCB
Celltech)
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animal. For example, it is sometimes necessary to balance
welfare against group sizes, but the authors believe that
welfare considerations should predominate. That is, it can be
preferable in principle to use more animals, with less suf-
fering to each individual (or better welfare), provided that
scientific integrity is not compromised.
Reporting animal use in RA studies
Literature reviews have identified serious issues with
the design, analysis and reporting of animal use in a
significant number of publications (Kilkenny et al.
2009; Baker et al. 2014; Bara and Joffe 2014; Moja
et al. 2014). The authors support the ARRIVE guide-
lines and believe that it is critically important to
include information on efforts made to replace animals,
reduce their use and suffering and improve their welfare
in materials and methods sections, or as supplementary
materials depending on the journal’s approach and
policy (Osborne et al. 2009). Posters and talks can also
include brief information on the three Rs, or supple-
mentary information can be included on flyers to
accompany poster presentations. This will help to dis-
seminate good practice and enable proper interpretation
of the results.
Table 6 Humane endpoints for mice and rats in RA studies
Adverse effect Humane endpoints and comments
Ulceration may develop in induced models, but with good
practice this should only occur in a small proportion of mice
and rats (\10 % in the authors’ experience)
The focus is generally not on diameter, but on whether there
are signs of healing, any secondary infection, ulcer depth,
whether the ulcer is wet, and behavioural signs of pain or
discomfort
However, if an ulcer diameter is[5 mm, the veterinarian or
senior animal technologist should be informed and consulted
about suitable treatment. The animal should be humanely
killed if there are no signs of healing within 3 days
Abnormal gaits and postures ‘Sledging’, i.e., pushing the tail down to compensate for two
painful hind paws
Difficulty holding food
Prolonged ([72 h) failure to weight bear on a limb
Severe paw swelling, assessed by visual scoring or using
callipers or plethysmography (Figs. 1, 2, 4)
Paw size increases may need to be corrected for growth
The researcher, animal technologists and veterinarian should
collaborate to define the maximum level of swelling, the
number of paws that may be affected, how this will be
assessed, and how long severe swelling should be permitted
to continue
Humane endpoints should always be implemented if swelling
forces the digits to splay, or encompasses the entire foot and
ankle, beginning to rise up the lower leg
Spontaneous vocalisation or squeaking and quivering when
picked up or handled
Arthritic rats can also vocalise in the cage when jostling with
cagemates
Rodents generally vocalise at ultrasonic frequencies, so audible
calls can indicate severe pain or distress
Absence of vocalisation does not indicate acceptable pain
levels, as clinical scores can reach humane end points
without audible vocalisation
Weight loss
Exceptions can be made for treatments expected to induce
weight loss, such as glucocorticoids
20 % is generally used in RA studies, or some protocols factor
in the duration, e.g., endpoint of 15 % loss that does not
begin to reverse within 5 days
Condition scoring can also be used, with scores that indicate
humane endpoints of additional food and/or hydration
support or humane killing
Study-specific end points
These involve an additional pain or anaesthesia burden, so
should be used only if data are available as part of the
scientific output of the study
Peripheral blood biomarkers may be used as earlier primary
indicators of the inflammatory response, rather than gross
inflammatory load, e.g., acute phase proteins or urinary
cartilage breakdown products might be present before
clinical deterioration and suffering
Data from imaging joints using X-ray or micro-computer
tomography (lCT), e.g., erosion and periostitis endpoints
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Recommendations for the future of RA research
using animals
Future work should aim to further reduce lifetime severity
in RA studies, whilst maintaining or even improving
opportunities for medical advances. This would be
achieved through the following:
• Further research into the use of analgesia, with respect
to suitable agents, effects on welfare and the science,
timing of administration and self-administration.
• A systematic review of the provision of analgesia in
arthritis experiments.
• Improved indicators of pain and distress, such as
accessible computer-assisted behavioural analysis.
• Less severe models, e.g., not requiring the use of
potentially severe inducers such as CFA.
• More physiologically relevant spontaneous models
using GA mice, which will decrease the number of
procedures because it will not be necessary to induce
RA.
• International guidelines for refined experimental pro-
tocols, including humane endpoints.
• Better sharing and publication of all three Rs in RA
studies.
• Greater support for the development and uptake of
in vitro, in silico and epidemiological approaches to RA
research.
Conclusion
The Working Group believes that there is considerable
scope to reduce the suffering and improve the welfare of
mice and rats in RA studies, and hopes that this resource
will support and encourage ongoing efforts towards this
important goal. Table 7 sets out some key recommenda-
tions taken from the text, which can be used as a check list
when designing, conducting or reviewing projects, to help
reduce severity and ensure that appropriate refinements
have been implemented wherever possible.
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Table 7 List of key recommendations to help refine the use of mice and rats in RA studies
Recommendation Sections
Review the sources of variation listed in Table 1 and ensure that each is addressed 2.3
Set out the whole life experience of each animal and consider how each potentially painful or distressing event could be
refined, using Table 2
3
Use the list of principles in Sect. 3 to review housing and husbandry, addressing any omissions 3
Critically question any statements that environmental enrichment has a negative impact on data quality; ask for empirical
evidence and be prepared to conduct or permit pilot studies if appropriate
3
If using an inducer, review its nature, formulation and administration protocol 3
If using LPS or CFA, review the justification and necessity and ensure appropriate refinements and humane endpoints 4
Review criteria for humane endpoints regarding ‘maximum end point responses’ and ‘therapeutic dosing regimes’. If
responsible for designing projects, suggest the topic for discussion by the ethics or animal care and use committee
4
For studies within the chronic resolving phase, critically review the model, the potential to reduce acute phase severity and
duration, welfare assessment protocols and humane endpoints
4
Review the justification and necessity for control groups, sharing these wherever possible without compromising the science,
and refining humane endpoints
4, 7
Do not assume that analgesia will negatively affect data. Use the literature, and undertake or permit pilot studies as necessary,
to evaluate the effects of analgesia on both welfare and science
5
Carefully consider how to administer analgesia, including pros and cons of gavage, parenteral- and self-administration 5.4
Keep up with developments in animal monitoring technology, e.g., new software, activity meters and thermography—avoiding
those that require single housing
6
Ensure that appropriate welfare assessment protocols are defined, and regularly reviewed, with a variety of inputs including the
veterinarian, researchers, animal technologists and the ethics or animal care and use committee
6
Implement the ‘R’ of reduction thoughtfully, ensuring that sufficient power is maintained while minimising numbers and
severity
8
Use the ARRIVE guidelines as a checklist when designing projects as well as when writing papers for publication 9
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Appendix
See Table 8.
Table 8 Generic example of a score sheet for mice used in rheumatoid arthritis studies
Inial body weight (g)
Minimum weight (g) 
= 0.8 × inial
Day 1 2 3 4
Body weight
0 – 5 % 0
5 – 10 % 1
10 – 15 % 2
≥15 % for up to 5 days a 4
20 % HEP
Coat condion
Normal 0
Lack of grooming 1
Staring coat 2
Mouse Grimace Scale
Not present 0
Moderate 1
Severe 2
Present for 24 h HEP
Behaviour
Isolated from cagemates 5
Arthric paw score (see table below)
Normal 0
Total 1 - 3 2
Total 4 – 6 4
Total 7 – 9 8
Total 10 or more HEP
Skin discolouraonb 6
Total score
Free text box for addional 
observaons
Paw scoring system: 0 = normal, 1 = digits swollen, 2 = digits and pad swollen, 3 = wrist/ankle, pad and digits swollen 
Day
Right front 0 –3
Le front 0 –3
Right back 0 –3
Le back 0 –3
Total
a If animals have lost 15 % or more of their body weight, weigh them daily.  Euthanase if no recovery is seen for 4 days or weight loss reaches 20 %..
b Skin discolouraon-an area of skin on the paw with a noceably different colour, e.g., redness where swelling has stretched the skin (Fig. 2) 
HEP = humane endpoint
Acons:
0 Normal, no acon required
1–5 Disease evident, monitor carefully
6–10 Implement pain management protocols
11–13 Seek advice from senior animal technologist or veterinarian; consider humane killing; if no senior animal technologist or 
veterinarian is available then euthanase the animal
14 HEP
This should be tailored to meet the characteristics and requirements of individual projects
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